Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric fesoterodine pharmacokinetic study in overactive bladder
2014-004161-24Phase 2
- Sponsor
- Pfizer
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fesoterodine in overactive bladder (OAB) and detrusor hyperreflexia (DH), sponsored by Pfizer. Primary endpoint: Model-based pharmacokinetic parameter estimates of 5-HMT.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on 2014-004161-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004161-24.